Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Phase 2 Interventional

Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis

NCT00924547
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexanoic Acid Supplement, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Not applicable Interventional

Pilot Study of a CF-specific CBT Intervention for Adolescents

NCT05271643
View directory record Official record
Conditions
Cystic Fibrosis, Depression, Anxiety
Interventions
Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Kansas City, Kansas • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03691779
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 13, 2026, 8:49 PM EDT
Recruiting No phase listed Observational

Sinus Disease in Young Children With Cystic Fibrosis

NCT06191640
View directory record Official record
Conditions
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 8:49 PM EDT
Withdrawn Not applicable Interventional

The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 2

NCT03522480
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
Jamboxx Respiratory Therapy Device, Autogenic Draining Training
Device · Other
Lead sponsor
My Music Machines Inc.
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 4 Interventional

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

NCT07632768
View directory record Official record
Conditions
Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions
Discontinuation of Pancreatic Enzyme Replacement Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
0 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 2 Interventional Results available

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

NCT01859390
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AquADEKs-2, control multivitamin
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 13, 2026, 8:49 PM EDT
Not yet recruiting Not applicable Interventional

Rethinking Early Airway Clearence Therapies

NCT07696338
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
As-needed hypertonic saline (HS), Twice daily hypertonic saline (HS), As-needed dornase alfa (DA), Daily dornase alfa (DA)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
3 Years to 16 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
552-02
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
14 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 13, 2026, 8:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exercise in Child Health

NCT05359991
View directory record Official record
Conditions
Cystic Fibrosis, Sickle Cell Disease, SARS CoV 2 Infection
Interventions
Exercise
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

NCT01705145
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 13, 2026, 8:49 PM EDT
Completed No phase listed Observational

Genetics of Mammographic Appearances and Patterns (The GenMap Study)

NCT01160510
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 13, 2026, 8:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls

NCT01331980
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Peripheral quantitative computed tomography (pQCT), Dual X-ray absorptiometry (DXA)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 12 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 13, 2026, 8:49 PM EDT
Completed No phase listed Observational

Cystic Fibrosis and Cognitive Function

NCT03820349
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 13, 2026, 8:49 PM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 8:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Cystic Fibrosis

NCT01379040
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Cystic Fibrosis patients
Other
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 13, 2026, 8:49 PM EDT
Withdrawn Not applicable Interventional

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

NCT05229640
View directory record Official record
Conditions
CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions
Fibroscan
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 13, 2026, 8:49 PM EDT
Not listed Not applicable Interventional

A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis

NCT06350149
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sugar Sweetened Beverages (SSB), Hi GI, Lo GI
Other
Lead sponsor
Emory University
Other
Eligibility
12 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Not applicable Interventional

Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis

NCT00788138
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 13, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

NCT04235140
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 8:49 PM EDT